Suchergebnisse - "Hu, Huabin"

PubPharm (5)

1

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer : The FOCULM Multicenter Phase II Trial

enthalten in: The oncologist | 2021

von Hu, H. | Wang, K. | Huang, M. | +25

2

TRIBE2 results and toxicity

enthalten in: The Lancet. Oncology | 2020

von Zhang, J. | Cai, Y. | Xie, X. | +2

CommentOn: Lancet Oncol. 2020 Apr;21(4):497-507. - PMID 32164906

3

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

enthalten in: Cancer control : journal of the Moffitt Cancer Center | 2020

von Han, J. | Xiao, D. | Tan, C. | +11

4

Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer

enthalten in: Clinical colorectal cancer | 2019

von Zhang, J. | Huang, M. | Cai, Y. | +18

5

Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer

enthalten in: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery | 2018

von Cai, Y. | Deng, R. | Hu, H. | +6

1
[1]